Gourt > Health > Pharmacy > Drugs and Medications > V > Valdecoxib
| 4-(5-methyl-3-phenyl-4-isoxazolyl)-benzenesulfonamide | |
| CAS number 181695-72-7 | ATC code M01AH03 |
| Chemical formula | C16H14N2O3S |
| Molecular weight | 314.364 |
| Bioavailability | 83% |
| Metabolism | 10% |
| Elimination half-life | 8-11 hours |
| Excretion | 90% |
| Pregnancy category | In late pregnancy, valdecoxib should be avoided because it may cause premature closure of the ductus arteriosus. |
| Legal status | Recalled in US, EU, Canada & parts of Asia |
| Routes of administration | 10mg Oral |
| Information Source: | |
Valdecoxib is a prescription drug used in the treatment of osteoarthritis, rheumatoid arthritis, and painful menstruation and menstrual symptoms. It is classified as a nonsteroidal anti-inflammatory drug, or NSAID, and should not be taken by anyone allergic to these types of medications.
Valdecoxib was manufactured and marketed under the brand name Bextra® by G. D. Searle & Company. It was available by prescription in tablet form until 2005, when it was removed from the market due to concerns about possible increased risk of heart attack and stroke.
More on [ Valdecoxib ]
Analgesics and Anti Inflammatories :: Drugs and Medications
Lornoxicam Lumiracoxib Meloxicam Naproxen Nimesulid Piroxicam Rofecoxib · Parecoxib Tenoxicam Valdecoxib si si IBUPROFEN
dihania (Dihania) Wed, 02 Dec 2009 23:05:11 -0000
Lornoxicam Lumiracoxib Meloxicam Naproxen Nimesulid Piroxicam Rofecoxib · Parecoxib Tenoxicam Valdecoxib si si IBUPROFEN
Food and Drug Administration (FDA) Bextra Consumer Information - Patient FAQ in html format with a link to approved labeling (as pdf).
Newly Approved Drug Therapies: Bextra - Information on US-approved uses and results of clinical trials, from CenterWatch.
Meta Description: [ Listing for Bextra in FDA Approved Drug Therapies Archives from CenterWatch Clinical Trials Listing Service ]
Valdecoxib - FamilyDoctor.org - Information for consumers in English or Spanish.
| Warnings for Bextra Strengthened (Feb 2003) | |
